HB139 requires most health insurance policies, hospital and medical service plans, mutual benefit society plans, and health maintenance organization contracts issued or renewed in Hawaii after December 31, 2025, to cover standard fertility preservation services for insureds who are likely to experience iatrogenic infertility from medically necessary treatment. The bill is aimed primarily at cancer-related treatment, defining the covered condition as infertility caused directly or indirectly by surgery, chemotherapy, radiation, or similar treatment affecting reproductive organs or processes. Coverage applies to the policyholder or covered person, and to covered individuals under age 26.
The bill also limits how insurers may apply exclusions or utilization controls. It bars denials or restrictions based on prior diagnosis, prior fertility treatment, life expectancy, disability, perceived quality of life, or other health conditions. Any limits must be tied to medical history and clinical guidelines, and those guidelines must be based on the 2018 American Society of Clinical Oncology fertility preservation guidelines without deviating from their full scope. The bill excludes experimental procedures, third-party assisted reproduction such as donor eggs, surrogacy, and gestational carriers, and cryopreservation storage services.
In state law, HB139 adds new mandatory-benefit provisions to chapters 431 and 432 and amends the HMO required-benefits statute so that HMOs must also provide the same fertility preservation coverage. The bill therefore expands Hawaii’s insurance benefit mandates and applies them across multiple regulated health coverage types. The measure is set to apply to policies and contracts issued or renewed after December 31, 2025, while the act itself carries a later effective date of December 31, 2050.
The overall sentiment reflected in the voting history is strongly favorable. The bill passed the Senate Health and Human Services Committee 5-0 with amendments, then passed the Senate Commerce and Consumer Protection Committee 5-0 and the Senate Ways and Means Committee 13-0, both without further amendment. That pattern suggests broad support for requiring fertility preservation coverage, especially for patients facing infertility as a consequence of medically necessary treatment.
The main points of contention, based on the text rather than recorded debate, are likely to involve the scope and cost of the mandate. The bill narrows coverage to ASCO-defined standard services and excludes experimental procedures, third-party assisted reproduction, and storage costs, which suggests an effort to balance access with insurer concerns. Potential issues for insurers and employers include premium impact, administrative implementation, and the breadth of the anti-discrimination language, while patient advocates would likely focus on access to fertility preservation for young adults and cancer patients.
HB139 would create a new mandated insurance benefit in Hawaii for standard fertility preservation services and require conforming changes to the HMO benefits statute. It would affect insurers, mutual benefit societies, health maintenance organizations, policyholders, and covered dependents under age 26, and would apply to policies and contracts issued or renewed after December 31, 2025. The bill would also incorporate ASCO clinical guidelines into coverage administration and prohibit certain exclusions and discriminatory coverage practices.
The available voting record shows unanimous committee approval at each recorded stage, indicating clear legislative support for the bill. The amendments appear to have been accepted without recorded opposition, suggesting the measure was viewed favorably as a patient-protection and coverage-expansion bill. No committee transcript was provided, so there is no direct record of debate, but the votes point to a broadly positive sentiment.
The likely areas of contention are the cost and scope of the new mandate, especially for insurers and employer-sponsored plans that would have to cover fertility preservation services. The bill attempts to limit controversy by tying coverage to established ASCO guidelines and excluding experimental procedures, assisted reproduction involving donors or surrogates, and cryopreservation storage. Another possible point of debate is the breadth of the anti-discrimination provisions and whether the mandate should extend to all covered persons or be limited more narrowly to specific diagnoses or age groups.